Literature DB >> 11549589

Inverse relation of Fas-ligand and tumor-infiltrating lymphocytes in angiosarcoma: indications of apoptotic tumor counterattack.

C Zietz1, U Rumpler, M Stürzl, U Löhrs.   

Abstract

Fas and Fas-L regulate immune responses through the induction of cell death. Fas-L is commonly expressed in activated immune cells and in the endothelium. In the latter it contributes to the inhibition of transvascular cell migration by the induction of apoptosis in Fas-bearing lymphocytes. Here we investigated whether the Fas/Fas-L system may regulate lymphocyte invasion into angiosarcomas. Fas and Fas-L expression was quantitatively determined in different grade angiosarcomas (n = 40) and related to the number of extravasated tumor-infiltrating lymphocytes (TILs). Fas expression was detected in < 50% of the cases. In positive tumors both the number of Fas-positive cells and the staining intensity were highly variable and did not correlate with the number of TILs, the mean time of survival, and the histopathological tumor grade. By contrast, Fas-L expression was detected in >70% of the cases and the relative numbers of Fas-L-positive cells correlated inversely with the numbers of CD3- and CD8-positive TILs (P < or = 0.004). The survival times of patients with high Fas-L-expressing angiosarcomas were significantly reduced as compared to patients with low Fas-L-expressing tumors. Our results show that angiosarcomas with low Fas-L expression are characterized by numerous TILs, whereas sarcomas with high Fas-L expression show significantly reduced numbers of TILs. These results suggest that the Fas/Fas-L system may repress TIL invasion into angiosarcoma and by this may contribute to the evasion of the anti-tumor immune surveillance of angiosarcoma in the course of an apoptotic tumor counterattack mechanism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11549589      PMCID: PMC1850461          DOI: 10.1016/S0002-9440(10)61772-5

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  30 in total

Review 1.  The Fas counterattack: cancer as a site of immune privilege.

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; J K Collins; F Shanahan
Journal:  Immunol Today       Date:  1999-01

2.  Fas counter-attack--the best form of tumor defense?

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; J K Collins; F Shanahan
Journal:  Nat Med       Date:  1999-03       Impact factor: 53.440

Review 3.  Negative regulation of inflammation by Fas ligand expression on the vascular endothelium.

Authors:  K Walsh; M Sata
Journal:  Trends Cardiovasc Med       Date:  1999 Jan-Feb       Impact factor: 6.677

4.  Immunohistochemical analysis of Fas ligand expression in sarcomas. Sarcomas express high level of FasL in vivo.

Authors:  S H Lee; J J Jang; J Y Lee; S Y Kim; W S Park; C S Kim; S H Kim; N J Yoo
Journal:  APMIS       Date:  1998-11       Impact factor: 3.205

5.  Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege.

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; J O'Callaghan; J K Collins; F Shanahan
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

6.  Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer.

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; D Roche; J Kelly; J K Collins; F Shanahan
Journal:  J Pathol       Date:  1998-11       Impact factor: 7.996

7.  Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase.

Authors:  N Mitsiades; V Poulaki; V Kotoula; A Leone; M Tsokos
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

8.  Endothelial cell apoptosis induced by oxidized LDL is associated with the down-regulation of the cellular caspase inhibitor FLIP.

Authors:  M Sata; K Walsh
Journal:  J Biol Chem       Date:  1998-12-11       Impact factor: 5.157

Review 9.  Is extravasation a Fas-regulated process?

Authors:  K Walsh; M Sata
Journal:  Mol Med Today       Date:  1999-02

10.  MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas.

Authors:  C Zietz; M Rössle; C Haas; A Sendelhofert; A Hirschmann; M Stürzl; U Löhrs
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

View more
  6 in total

Review 1.  Fas ligand and the fate of antitumour cytotoxic T lymphocytes.

Authors:  Joe O'Connell
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

2.  Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma.

Authors:  S Théoleyre; K Mori; B Cherrier; N Passuti; F Gouin; F Rédini; D Heymann
Journal:  BMC Cancer       Date:  2005-09-27       Impact factor: 4.430

3.  A quest for therapeutic antigens in bone and soft tissue sarcoma.

Authors:  Satoshi Kawaguchi; Takuro Wada; Tomohide Tsukahara; Kazunori Ida; Toshihiko Torigoe; Noriyuki Sato; Toshihiko Yamashita
Journal:  J Transl Med       Date:  2005-08-08       Impact factor: 5.531

4.  Positive PD-L1 Expression Predicts Worse Outcome in Cutaneous Angiosarcoma.

Authors:  Akira Shimizu; Kyoichi Kaira; Yuko Okubo; Daisuke Utsumi; Masahito Yasuda; Takayuki Asao; Masahiko Nishiyama; Kenzo Takahashi; Osamu Ishikawa
Journal:  J Glob Oncol       Date:  2016-10-05

5.  Association between RCAS1 expression and clinical outcome in uterine endometrial cancer.

Authors:  K Sonoda; S Miyamoto; T Hirakawa; T Kaku; M Nakashima; T Watanabe; K Akazawa; T Fujita; H Nakano
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640

6.  Effect of reactive oxygen species generation in rabbit corneal epithelial cells on inflammatory and apoptotic signaling pathways in the presence of high osmotic pressure.

Authors:  Yihui Chen; Min Li; Bing Li; Weifang Wang; Anjuan Lin; Minjie Sheng
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.